基质金属蛋白酶-2和血管内皮生长因子在肝癌肝移植受体的表达和意义

Expression and Clinical Significance of MMP-2 and VEGF in Recipients of Hepatocellular Carcinoma Accepted Liver Transplantation

【目的】探讨基质金属蛋白酶-2(MMP-2)和血管内皮生长因子(VEGF)在肝癌肝移植受体中的表达和意义。【方法】肝移植受体分为4组:供体组(n=60),肝硬化组(n=60),肝癌无癌栓组(n=45)和肝癌有癌栓组(n=35),分别用ELISA法测定4组血MMP-2和VEGF浓度;荧光定量PCR法测定4组肝脏标本MMP-2 mRNA和VEGF mRNA的表达量。肝癌受体接受肝移植术后,随访了解肿瘤的复发情况,并测定血MMP-2、VEGF浓度。【结果】供体组、肝硬化组、HCC无癌栓组和HCC有癌栓组的MMP-2浓度(ng/mL)分别为7.2±2.5、30.3±19.5、84.5±45.3和151.6±83.6(P<0.01);4组VEGF浓度(pg/mL)分别为155.6±21.7、200.3±73.9、283.7±104.3和371.1±99.3(P<0.01);供体组、肝硬化组、HCC无癌栓组和HCC有癌栓组的MMP-2 mRNA表达量(对数值)分别为4.9±1.3、7.2±5.5、11.2±7.6和19.0±9.2拷贝数/μL(P<0.01);4组VEGF mRNA表达量(对数值)分别为11.4±2.1、13.5±6.3、19.7±8.4和24.7±11.8拷贝数/μL(P<0.01)。肝癌有癌栓组肝移植术后肿瘤复发率为66.67%,高于无癌栓组(P<0.01)。【结论】MMP-2和VEGF在肝癌肝移植受体呈高表达,与肿瘤的侵袭和转移行为密切相关,可作为肝癌肝移植受体选择和术后随访评判复发风险的因素。

[Objective] To investigate the expression and clinical significance of MMP-2 and VEGF in recipient of HCC accepted orthotropic liver transplantation （OLT）. [Methods] Recipients were divided into 4 groups： the donor group （n = 60）, liver fibrosis group （n = 60）, HCC without tumor thrombi group （n = 45） and HCC with tumor thrombi group （n = 35）. The serum concentration of MMP-2 and VEGF were assayed by ELISA. The expression of MMP-2 mRNA and VEGF mRNA in liver of patients were detected by fluorescent quantization polymerase chain reaction. Recipient of HCC were followed after accepted OLT and the serum concentration of MMP-2 and VEGF were assayed by ELISA. [ Results ] The serum concentration of MMP-2 were 7.2 ±2.5, 30.3 ± 19.5, 84.5± 45.3, and 151.6± 83.6 ng/mL （P 〈 0.01 ） in the donor group, liver fibrosis group, HCC without tumor thrombi group and HCC with tumor thrombi group. The serum concentration of VEGF were 155.6± 21.7, 200.3± 73.9, 283.7 ±104.3, and 371.1 ± 99.3 pg/mL （P〈 0.01） in the 4 groups. The expression of MMP-2 mRNA were 4.9 ± 1.3, 7.2 ± 5.5, 11.2 ± 7.6, and 19.0 ± 9.2 copy number/μL logarithm value in the 4 groups, the expression of VEGF mRNA were 11.4± 2.1, 13.5 ±6.3, 19.7± 8.4, and 24.7± 11.8 copy number/μL logarithm value in the 4 groups（P 〈 0.01）. The recurrence rate of carcinoma in recipient of HCC with tumor thrombi was 66.67%, higher than HCC without tumor thrombi after OLT （P 〈 0.01）. [Conclusion] The expression of MMP-2 and VEGF are highly correlated with invasion and metastasis in recipients of HCC accepted OLT, which may serve as a parameter for determining tumor metastasis and prognosis. It may be a new idea to choose and supervise the recipient of HCC for OLT.